Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS
The Pharma Data
OCTOBER 18, 2021
Tofersen binds to SOD1 mRNA, allowing for its declination by RNase-H in an trouble to reduce conflation of SOD1 protein product. under a cooperative development and license agreement. About Tofersen Tofersen is an antisense medicine being estimated for the implicit treatment of SOD1-ALS.
Let's personalize your content